Sriram Ganapathy

Sriram Ganapathy is a scientist specializing in immunology, currently working at Flagship Labs 65 Inc. in Cambridge, Massachusetts. His professional focus is on leveraging immuno-oncology to develop innovative cancer therapies, particularly through the integration of chemotherapy and immune stimulants to enhance anti-cancer responses. He has been involved in developing cancer vaccines aimed at effective cancer management.1

Educational Background

• Bachelor of Engineering (BEng), Biotechnology
  PES Institute of Technology (2003 - 2007)

• Doctor of Philosophy (PhD), Biochemistry and Cancer Biology
  Rutgers University (2008 - 2014)

Professional Experience

• Scientist - Immunology
  Flagship Labs 65 Inc. (October 2020 - July 2021)

• Senior Scientist, Immuno-Oncology
  EMD Serono, Inc. (August 2021 - March 2024)

• Postdoctoral Researcher
  Massachusetts Institute of Technology (MIT) (March 2015 - October 2020)

• Postdoctoral Fellow
  Rutgers University (June 2014 - February 2015)

Research Interests

Ganapathy's research interests include cancer biology and immunology, with a particular emphasis on the development of therapies that combine immune modulation with traditional cancer treatments. His work aims to create lasting anti-cancer effects through innovative therapeutic strategies.1